A historical study recently published in March 2025 by JCO oncology advanced, demonstrates the potential of TrackTM In monitoring treatment and assessment of recurrence in 623 solid tumor patients of six types of cancer (lung, colorectal, breast, gastric, hepatic or ovary cancer).(1)
SINGAPORE,, April 19, 2025 / Prnewswire / – Genetic solutionsa biotechnology company dedicated to the progression of precision oncology Asiais delighted to announce the publication of a pioneering study of the real world in advances in JCO oncology, validating circulating tumor DNA (DNAD) as a strong prognostic biomarker to effectively monitor patients during cancer management.
TrackTM is a breakthrough in affordable tumor profiling and personalized cancer monitoring by taking advantage of DNA technology. Study, the first of its kind in AsiaConfirm K-TrackTMClinical value of all early and advanced stages of cancer. The test can detect residual cancer cells (minimum residual disease – MRD) After radical treatment, predict recurrence of months earlier than traditional methods and effectively monitor treatment responses. This innovative double test offers patients to patients in poorly served regions where access to advanced diagnostic technologies remains a challenge.
Asia represents almost 50% of global cancer cases, the incidence rates increasing at an alarming rate. While certain markets developed in the region have experienced improvements in cancer mortality rates, Southeast Asia Continue to undergo high mortality rates, mainly pulled by recurrence of cancer. (2.3)
Research has demonstrated the DNA clinical prognostic value in a variety of cancer types before and after treatment (4). Despite this potential, the adoption of DNA tests remains limited due to factors such as high costs, the absence of standardized methods and the insufficient clinical utility of the real world.
TrackTM has been developed as a personalized and reliable test to monitor DNA on several solid tumors. It is designed to facilitate early detection of cancer recurrence and provide real -time monitoring of responses to treatment. Validated in clinical trials and real world studies, K-TrackTM is designed for a significant impact on cancer care while guaranteeing accessibility. Here’s how we operate it:
- Profitable innovation: TrackTM Uniquely combines the rationalized tumor profiling of 155 of the most common driver mutations with personalized DNA DNA monitoring based on specific variants, considerably improving the affordability and precision of the clinical routine practice.
- Complete approach to genomic profiling and minimal monitoring of residual diseases: The initial results of tumor profiling guide the selection of therapies and targeted immunotherapy, while series monitoring of series in series provides an early prediction of recurrence and evaluating the efficiency of the treatment.
- Designed for real world conditions: TrackTM is designed to provide reliable results even from difficult samples such as degraded tissues or delayed blood storage, which makes it ideal for complex clinical environments.
Surveillance of the actual world of DNA has proven to be effective in predicting early recurrence of cancer, allowing timely interventions and improving the results of patients. In patients with cancer at the early stage and advanced, K-TrackTM has demonstrated great precision in the forecast of the recurrence. After surgery, 84.4% [CA1] Patients with positive results in CTDNA finally relapsed, while an impressive 96.3% [CA2] Among those who have negative DNA results have remained without cancer. In addition, the test could detect the relapse up to 5.5 to 9.5 months earlier than clinical diagnosis by imaging methods. Simultaneously, the six case studies presented illustrated the clinical utility of DNA monitoring to predict the response to treatment, informing the decisions of adjuvant chemotherapy and identifying new changes resistant to current targeted treatment. Thus, empower clinicians with real and usable information to inform processing decisions.
A vision of fair care
“Access to personalized and personalized cancer treatment and monitoring – based on tumor genomic profiling – depends too often on where you live or what you can afford,” said Dr. LAN N. YouPrincipal researcher at Gene Solutions. “Our mission with K-TrackTM is to fill this gap by providing an affordable and precise real -time solution for clinical routine use. “”
Gene Solutions actively invests in two key areas:
1. Current clinical trials and real studies::
The company conducts complete research to validate the role of DNAs through various types of cancer and treatment steps. This includes the evaluation of responses to TKIS and immune control point inhibitors (here) in lung cancer, neoadjuvant treatment in breast cancer, total neoadjuvant therapy in rectum cancer and the use of biomarkers to shed light on the treatment of immunotherapy in advanced cancers.
2. Biopharmatic collaborations::
Gene Solutions actively pursues partnerships with biopharmaceutical companies to provide innovative solutions aimed at accelerating the development of drugs in a range of therapeutic methods. While scientific evidence supporting DNA continues to grow, Gene Solutions undertakes to extend her research and promote collaborations with current and new partners to explore new applications in cancer care. The management of the company aligns on the recommendation of the FDA on the use of DNAs as a biomarker in the development of healing therapies for solid tumors which declares: “DNA as a biomarker has a number of potential regulatory and clinical uses in early stage that can help and accelerate the development of drugs.” (5)
About genetic solutions
Gene solutions, a multinational biotechnology company in Asiaopens the way by taking advantage of advanced AI and DNA technologies for innovative cancer detection solutions. The company is associated with more than 4,500 hospitals and clinics Southeast Asia And employs a dedicated team of approximately 250 biology and technician experts out of a total of 700 employees.
With more than 50 publications evaluated by peers and more than 50 multicenter studies carried out in the region, Gene Solutions is recognized for its new generation owner and sequencing laboratories (NGS) Singapore And Vietnam. By integrating multidimensional genomics with AI methodologies, the company is committed to transforming care against cancer and improving patient results.
- Hoang, V.-An et al. (2025) “Use and performance of the real world of tumor DNA monitoring circulating to predict recurrence in solid tumors”, JCO ONCOLOGY advances, volume 2. DOI: 10.1200 / OA-24-00084
- Huang, J. et al. (2022) “Incidence of cancer and mortality in Asian countries: an analysis of trends”, “Cancer Control, 29. DOI: 10.1177 / 10732748221095955.
- Sharma, R. et al. (2024) “Temporal models of cancer load Asia1990-2019: a systematic examination of the Global Burden of Disease study 2019, “The Lancet Regional Health – Southeast Asia21, p. 100333. Two: 10.1016 / J.LANSA.2023.10033.
- Kobayashi, S. et al. (2025) ‘Japan Position position of the Society of Clinical Oncology on the appropriate clinical use of residual molecular disease tests (MRD), “International newspaper of clinical oncology [Preprint]. Two: 10.1007 / S10147-024-02683-0.
- Use of tumor DNA circulating for the development of solid tumor drugs with curative intention. (2024). As an industry guide [Clinical/Medical]. Guidances de la FDA, content current at: 01/17/2025.
Show original content to download the multimedia:https://www.prnewswire.com/apac/news-releases/asias-first-real-world-ctdna-mrd-study-sthendringhens-for-for–Effective-cancer-monitoring-302432926.html
Source gene solutions Genomics Pte Ltd
